ZIOPHARM Oncology (NASDAQ:ZIOP) Shares Cross Above 50 Day Moving Average of $5.05

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $5.05 and traded as high as $6.07. ZIOPHARM Oncology shares last traded at $5.97, with a volume of 51,407 shares trading hands.

A number of equities analysts have recently issued reports on ZIOP shares. Laidlaw started coverage on shares of ZIOPHARM Oncology in a report on Monday, April 1st. They issued a “buy” rating and a $7.50 price target for the company. BidaskClub upgraded shares of ZIOPHARM Oncology from a “buy” rating to a “strong-buy” rating in a report on Monday, June 17th. Zacks Investment Research upgraded shares of Zurich Insurance Group from a “sell” rating to a “hold” rating in a report on Saturday, May 18th. HC Wainwright increased their price target on shares of Palatin Technologies from $5.00 to $6.00 and gave the company a “buy” rating in a report on Thursday, May 9th. Finally, Lake Street Capital set a $30.00 price target on shares of TheStreet and gave the company a “buy” rating in a report on Thursday, April 4th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $5.75.

The company’s fifty day moving average price is $5.12. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.89 and a current ratio of 8.89. The company has a market cap of $908.23 million, a price-to-earnings ratio of -11.83 and a beta of 2.66.

ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.01. On average, analysts predict that ZIOPHARM Oncology Inc. will post -0.33 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of ZIOP. Rhumbline Advisers grew its stake in ZIOPHARM Oncology by 46.5% in the 4th quarter. Rhumbline Advisers now owns 175,080 shares of the biotechnology company’s stock valued at $327,000 after acquiring an additional 55,579 shares during the last quarter. Private Advisor Group LLC grew its stake in ZIOPHARM Oncology by 21.5% in the 4th quarter. Private Advisor Group LLC now owns 141,132 shares of the biotechnology company’s stock valued at $264,000 after acquiring an additional 24,966 shares during the last quarter. Raymond James Financial Services Advisors Inc. acquired a new stake in ZIOPHARM Oncology in the 4th quarter valued at about $88,000. Northern Trust Corp grew its stake in ZIOPHARM Oncology by 0.5% in the 4th quarter. Northern Trust Corp now owns 1,647,754 shares of the biotechnology company’s stock valued at $3,081,000 after acquiring an additional 8,068 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in ZIOPHARM Oncology by 10.3% in the 4th quarter. Geode Capital Management LLC now owns 1,552,016 shares of the biotechnology company’s stock valued at $2,902,000 after acquiring an additional 145,129 shares during the last quarter. 38.75% of the stock is currently owned by hedge funds and other institutional investors.

ZIOPHARM Oncology Company Profile (NASDAQ:ZIOP)

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

See Also: How to interpret a stock’s beta number

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.